- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07280156
En studie for å undersøke den kliniske effekten og sikkerheten av PRX-115 infundert intravenøst med ulike doseringsregimer, med og uten metotreksat, kontra placebo hos voksne pasienter med gikt (RELEASE) (RELEASE)
Et multicenter, randomisert, dobbeltblindet, placebokontrollert, fase 2-studie som vurderer effekt, sikkerhet og doseringsregimvalg av multiple intravenøse infusjoner av PRX-115 med og uten metotreksat versus placebo hos voksne pasienter med gikt (RELEASE)
This is a multicenter, randomized, double-blind, placebo-controlled phase II study assessing the efficacy, safety, and dosing regimen selection of multiple IV infusions of PRX-115 over 24 weeks, with or without MTX, versus the respective placebos in adult patients with gout.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This study will evaluate the efficacy, safety, tolerability, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of PRX-115 (a recombinant pegylated Uricase) in adult patients with gout. Participants will receive PRX-115 by intravenous (IV) infusions according to different treatment schedules, with and without the immunomodulator methotrexate (MTX).
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Head of Clinical Development
- Telefonnummer: +972-4-902-8100
- E-post: info@protalix.com
Studiesteder
-
-
Arizona
-
Glendale, Arizona, Forente stater, 85306
- Rekruttering
- Rezen Clinical Trials
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- Rekruttering
- Applied Research Center of Arkansas
-
-
California
-
Anaheim, California, Forente stater, 92805
- Rekruttering
- Advanced Research Center, Inc
-
El Cajon, California, Forente stater, 91910
- Rekruttering
- Triwest Research Associates Llc
-
La Palma, California, Forente stater, 90623
- Rekruttering
- Imax Clinical Trials, LLC
-
Long Beach, California, Forente stater, 90806
- Rekruttering
- Kinetic Clinical Research
-
-
Florida
-
Clearwater, Florida, Forente stater, 33765
- Rekruttering
- Clinical Research of West Florida, Inc.
-
DeLand, Florida, Forente stater, 32720
- Rekruttering
- Accel Research Sites - Deland Clinical Research Unit
-
Doral, Florida, Forente stater, 33125
- Rekruttering
- ICR Sites East
-
Hialeah, Florida, Forente stater, 33010
- Rekruttering
- Qway Research
-
Miami, Florida, Forente stater, 33155
- Rekruttering
- Bioclinical Research Alliance, Inc
-
Miami, Florida, Forente stater, 33169
- Rekruttering
- D&H National Research Centers (North Miami)
-
Miami, Florida, Forente stater, 33173
- Rekruttering
- Well Pharma Medical Research Group
-
Orlando, Florida, Forente stater, 32832
- Rekruttering
- Conquest Research - Lake Nona
-
Orlando, Florida, Forente stater, 32897
- Rekruttering
- Combined Research Orlando Phase I-IV
-
Palmetto Bay, Florida, Forente stater, 33176
- Rekruttering
- New Horizons Research
-
Tampa, Florida, Forente stater, 33606
- Rekruttering
- Clinical Research of West Florida, Inc.
-
-
Georgia
-
Columbus, Georgia, Forente stater, 31904
- Rekruttering
- Centricity Research - Columbus Georgia Multispecialty
-
-
Michigan
-
Dearborn, Michigan, Forente stater, 48126
- Rekruttering
- Revival Research Institute, LLC
-
Farmington Hills, Michigan, Forente stater, 48334
- Rekruttering
- Quest Research Institute
-
Sterling Heights, Michigan, Forente stater, 48313
- Rekruttering
- Revive Research Institute, Inc
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Forente stater, 16635
- Rekruttering
- Altoona Center for Clinical Research
-
-
Texas
-
Houston, Texas, Forente stater, 77099
- Rekruttering
- Pioneer Research Solutions Inc
-
Sugar Land, Texas, Forente stater, 77479
- Rekruttering
- Mt. Olympus Medical Research, LLC - Sugar Land
-
Waco, Texas, Forente stater, 76710
- Rekruttering
- Velocity Clinical Research
-
-
Virginia
-
Suffolk, Virginia, Forente stater, 23435
- Rekruttering
- Velocity Clinical Research
-
-
-
-
-
Tbilisi, Georgia, 0102
- Rekruttering
- Aleksandre Aladashvili Clinic LLC, Georgia
-
Tbilisi, Georgia, 0159
- Rekruttering
- Tbilisi Heart and Vascular Clinic Ltd , Georgia
-
Tbilisi, Georgia, 0160
- Rekruttering
- Mediclub Georgia
-
Tbilisi, Georgia, 0160
- Rekruttering
- Tbilisi Institute of Medicine, Georgia
-
Tbilisi, Georgia, 0172
- Rekruttering
- Georgian-Dutch Hospital, Georgia
-
Tbilisi, Georgia, 0180
- Rekruttering
- LTD First Medical Center, Georgia
-
-
-
-
-
Afula, Israel, 1834111
- Rekruttering
- HaEmek MC, Israel
-
Ashkelon, Israel, 7830604
- Rekruttering
- Barzilai MC, Israel
-
Kfar Saba, Israel, 4438164
- Rekruttering
- Meir MC, Israel
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Males or females ≥18 years of age.
- Weight within the range of 50.0 - 150.0 kg.
- Gout patients who failed to normalize sUA (<7 mg/dL) with or without xanthine oxidase inhibitors or uricosuric agent or have contraindications to these drugs.
- Willing to discontinue any oral ULT
- Females who are sterile, postmenopausal, or non-pregnant and using birth control methods.
Exclusion Criteria:
- Any condition known to have arthritis as a clinical manifestation.
- Positive testing for HBV,HCV, or HIV.
- The patient is a pregnant or lactating female or plans to become pregnant during the study period.
- Known allergy or sensitivity to the injected proteins, including pegylated products.
- Prior exposure to any experimental or marketed uricase.
- Patient treated with a medication known to have an influence on urate metabolism or clearance such as ULTs.
- History of anaphylaxis, severe allergic reactions, or severe atopy.
- G6PD deficiency or known catalase deficiency.
- History of significant hematologic or autoimmune disorders within 5 years of Screening and/or patient is immunocompromised or treated with immunosuppressive medications.
- Non-compensated CHF or hospitalization for CHF (Stage 3-4 NYHA Functional Class) within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled BP (>160/100 mmHg) at screening and prior to randomization at Week -4 (Visit 1).
- Current liver disease, as determined by ALT or AST levels above upper limit of normal at Screening Visit.
- Chronic liver disease.
- Hemoglobin <11 g/dL, neutrophil count <1500 /µl, or platelet count <100,000 /µl.
- Known severe pulmonary fibrosis, bronchiectasis or interstitial pneumonitis.
- eGFR ≤ 40 mL/min/1.73m2 tested at Screening Visit. Kidney transplant or requires dialysis.
- Known intolerance and/or known contraindication to MTX treatment or MTX treatment considered inappropriate
- Has uncontrolled type 2 diabetes at Screening with HbA1c ≥8.5%. Patients with type 1 diabetes will be excluded.
- Has known latent autoimmune diabetes of adult.
- Immunocompromised state, regardless of etiology.
- History or treatment of malignancy in the last 5 years, excluding localized, nonmelanoma skin cancers (e.g. basal or squamous cell)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: E4W with placebo-MTX
IV infusion of PRX-115 every 4 weeks (E4W) for a total of 6 doses with placebo-MTX |
intravenous (IV) infusion Oral Placebo-MTX weekly |
|
Eksperimentell: E4W with MTX
IV infusion of PRX-115 every 4 weeks (E4W) for a total of 6 doses with MTX |
intravenous (IV) infusion Oral MTX 15 mg weekly |
|
Eksperimentell: E6W with MTX
IV infusion of PRX-115 every 6 weeks (E6W) for a total of 4 doses with MTX |
intravenous (IV) infusion Oral MTX 15 mg weekly |
|
Eksperimentell: E8W with MTX
IV infusion of PRX-115 every 8 weeks (E8W) for a total of 3 doses with MTX |
intravenous (IV) infusion Oral MTX 15 mg weekly |
|
Placebo komparator: placebo E4W
infusion of PRX-115 placebo every 4 weeks (E4W) for a total of 6 doses with placebo-MTX |
Oral Placebo-MTX weekly intravenous (IV) infusion |
|
Placebo komparator: placebo E6W
IV infusion of PRX-115 placebo every 6 weeks (E6W) for a total of 4 doses with placebo-MTX |
Oral Placebo-MTX weekly intravenous (IV) infusion |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
Tidsramme: 6 months of treatment
|
Proportion of patients who achieve a reduction in sUA to <6.0 mg/dL for at least 80% of the time during Month 6 |
6 months of treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) at different time points
Tidsramme: 3 to 6 months of treatment
|
Proportion of patients that achieve a reduction in sUA to <6.0 mg/dL for at least 80% of the time during Month 3 or 4, 5 and 6. |
3 to 6 months of treatment
|
|
Treatment-emergent adverse events (TEAEs)
Tidsramme: From enrollment to 8 months of study
|
Occurrence and severity of treatment-emergent adverse events (TEAEs) |
From enrollment to 8 months of study
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Krystallarthropatier
- Muskel- og skjelettsykdommer
- Patologiske prosesser
- Leddgikt
- Leddsykdommer
- Revmatiske sykdommer
- Purin-Pyrimidin-metabolisme, medfødte feil
- Metabolisme, medfødte feil
- Genetiske sykdommer, medfødte
- Metabolske sykdommer
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Patologiske tilstander, tegn og symptomer
- Ernæringsmessige og metabolske sykdommer
- Gikt
- Hyperurikemi
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Pteriner
- Pteridiner
- Aminopterin
- Metotreksat
Andre studie-ID-numre
- PB115-GT-201
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .